Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas

被引:77
作者
Edmunds, SC
Cree, IA [1 ]
Dí Nícolantonío, F
Hungerford, JL
Hurren, JS
Kelsell, DP
机构
[1] Queen Alexandra Hosp, Translat Oncol Res Ctr, Portsmouth PO6 3LY, Hants, England
[2] Univ London, Barts & London Sch Med & Dent, Ctr Cutaneous Res, London E1 2AT, England
[3] Inst Ophthalmol, Dept Pathol, London EC1V 9EL, England
[4] Moorfields Eye Hosp, London EC1V 9EL, England
[5] Queen Alexandra Hosp, Dept Surg, Portsmouth PO9 6AH, Hants, England
关键词
melanoma; BRAF; DNA sequence; mutation;
D O I
10.1038/sj.bjc.6600919
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The recent discovery of activating mutations in the BRAF gene in many cutaneous melanomas led us to screen the genomic sequence of BRAF exons 11 and 15 in a series of 48 intraocular (uveal) melanomas, together with control samples from three cutaneous melanomas and the SK-Mel-28 cell line, which has a BRAF mutation. The same mutation was detected in two-thirds of our cutaneous melanoma samples, but was not present in any uveal melanomas. This finding further underlines the distinction between uveal and cutaneous melanomas, and suggests that BRAF inhibitors are unlikely to benefit patients with uveal melanoma. (C) 2003 Cancer Research UK.
引用
收藏
页码:1403 / 1405
页数:3
相关论文
共 22 条
[1]   TREATMENT OF METASTATIC UVEAL MELANOMA - REVIEW AND RECOMMENDATIONS [J].
ALBERT, DM ;
NIFFENEGGER, AS ;
WILLSON, JKV .
SURVEY OF OPHTHALMOLOGY, 1992, 36 (06) :429-438
[2]  
Brose MS, 2002, CANCER RES, V62, P6997
[3]   Malignant melanoma: modern black plague and genetic black box [J].
Chin, L ;
Merlino, G ;
DePinho, RA .
GENES & DEVELOPMENT, 1998, 12 (22) :3467-3481
[4]   Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: Potential for pharmacodynamic monitoring of signal transduction inhibitors [J].
Chow, S ;
Patel, H ;
Hedley, DW .
CYTOMETRY, 2001, 46 (02) :72-78
[5]   Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group Report [J].
Coudert, B ;
Anthoney, A ;
Fiedler, W ;
Droz, JP ;
Dieras, V ;
Borner, M ;
Smyth, JF ;
Morant, R ;
de Vries, MJ ;
Roelvink, M ;
Fumoleau, P .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (17) :2194-2198
[6]  
Cripps MC, 2002, CLIN CANCER RES, V8, P2188
[7]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[8]  
Demunter A, 2001, CANCER RES, V61, P4916
[9]  
Dolin P J, 1994, Ophthalmic Epidemiol, V1, P27, DOI 10.3109/09286589409071442
[10]  
Edmunds SC, 2002, INVEST OPHTH VIS SCI, V43, P2845